Antibodies in the treatment of lymphoma.
Leonard
John P
JP
Oncology Services, Weill Medical College of Cornell University, New York Presbyterian Hospital, NY, USA.
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000628:therapy; D016399:Lymphoma, T-Cell / Q000276:immunology / Q000628:therapy; D015337:Multicenter Studies as Topic; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000951:Antigens, Neoplasm; C448700:epratuzumab; D000069283:Rituximab; C448699:apolizumab